Emergency department throughput is dictated by acute decision bottlenecks, none more volatile than acute chest pain triage. When a patient arrives with substernal pressure and an equivocal electrocardiogram, the clinical team faces an unyielding operational tradeoff: activate the cardiac catheterization team at significant cost, or order serial troponins and wait hours while ischemic myocardium remains under-perfused.
The FDA's decision to grant De Novo authorization to Powerful Medical's PMcardio Queen of Hearts model converts this diagnostic friction into a standardized, cleared clinical workflow. In this deep dive, we examine the regulatory classification, hospital balance sheet impact, liability insulation, and competitive taxonomy of acute cardiac decision intelligence.
